Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tumor RNA Disruption Assay as a Tool to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer: Optimizing Timing of Biopsy

NCT02190227 is registered in ClinicalTrials.gov with Jewish General Hospital as lead sponsor.

NCT NCT02190227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02190227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tumor RNA Disruption Assay as a Tool to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer: Optimizing Timing of Biopsy
Lead sponsor
Jewish General Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2013
Completion date
September 30, 2014
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast cancer